Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LabCorp (LH) delivered earnings and revenue surprises of 3.91% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Surpasses Q1 Earnings Estimates

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2022, and updated full-year guidance. “Labcorp continues to advance our strategy through science, innovation and technology,” said Adam Schechter, chairman and CEO of Labcorp. “We delivered a solid first quarter despite the impact of Omicron. We remain focused on growth opportunities while continuing to take actions to mitigate inflation. O

Labcorp Announces 2022 First Quarter Results

Bio-Rad Laboratories

ResMed

Thermo Fisher Scientific

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp's diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes. With the service, individuals can now schedule a home blood draw or specimen collection when it's convenient for them. Appointments are available through Labcorp.com. Getlabs provi

Labcorp Launches Convenient Home Diagnostic Test Collection Service in Collaboration With Getlabs

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is collaborating with Xcell Biosciences, Inc. (Xcellbio), a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market. Through their collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). This strengthen

Labcorp Enhances Cell and Gene Therapy Development Support Through Collaboration With Xcell Biosciences

San Diego, California--(Newsfile Corp. - April 18, 2022) - Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Laboratory Corporation of America Holdings ("Labcorp" or the "Company") (NYSE: LH) and its officers and directors for violations of federal securities laws.On January 1, 2022, New York Times released an article regarding the efficacy of Labcorp and other screening labs for certain prenatal tests. The article states that, "A Labcorp MaterniT21 lab report tells...

(LH) News: Have You Lost Money on Your Labcorp Investment? Contact Johnson Fistel Regarding Investigation

Laboratory Corp. of America Holdings LH, +0.24% , also known as Labcorp, said Thursday that it has initiated a quarterly dividend of 72 cents a share. Shareholders of record on May 19 will be paid the dividend on June 9.

Labcorp initiates dividend, with an initial implied yield above 1%

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 9, 2022, to stockholders of record as of the close of business on May 19, 2022. The declaration and payment of the dividend is consistent with Labcorp's previously announced intention to initiate paying quarterly dividends beginning in the second

Labcorp Initiates Quarterly Dividend

LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.

LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2022 before the market opens on Thursday, April 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by

Labcorp to Announce First Quarter Financial Results on April 28, 2022

Let's see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider LabCorp (LH) Stock Now?

San Diego, California--(Newsfile Corp. - March 20, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Laboratory Corporation of America Holdings ("Labcorp" or the "Company") (NYSE: LH), any of its executive officers, or others violated federal securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.What is Johnson Fistel investigating? On January 1, 2022, New York Times released an article regarding the efficacy of Labcorp and other...

(LH) News: Contact Leading Law Firm Johnson Fistel Regarding Investigation

Laboratory Corporation of America Holdings has exhibited some nice growth over the past few years, driven in large part by the pandemic.

Laboratory Corporation Of America: An Undervalued Play In The Life Sciences Space

In the latest trading session, LabCorp (LH) closed at $274.33, marking a +0.11% move from the previous day.

LabCorp (LH) Gains But Lags Market: What You Should Know

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is the first U.S. commercial laboratory to offer a new test developed by Immundiagnostik, Inc. to help individuals detect and quantify unintentional gluten consumption. As awareness of celiac disease and non-celiac gluten sensitivity (NCGS) increases in the United States and around the globe, more people are adhering to strict diets to avoid gluten exposure and the negative effects it can have on thei

New Labcorp Offering Makes Detecting, Measuring Unintentional Gluten Consumption Simple and Effective

Burlington Stores

Lennar

When a company's return on equity ratio is superior to most of its competitors, it generally indicates the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks since they are performing better than most of their peer group companies in terms of a higher ROE ratio.

3 Stocks With High Returns on Equity

Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.

Here's Why You Should Hold on to LabCorp (LH) Stock For Now

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is entering into a strategic laboratory relationship with Prisma Health, a nonprofit and the largest health system in South Carolina. Through this new relationship, Labcorp will acquire select assets of Prisma Health's outreach laboratory business. In addition, Labcorp and Prisma Health have entered into a technical support agreement to apply Labcorp's knowledge and expertise in Prisma Health's hospit

Labcorp Enters Into Strategic Relationship With Prisma Health

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp's existing liquid biopsy capabilities and expands Labcorp's leading oncology portfolio of next-generation sequencing (NGS)-based g

Labcorp Completes Acquisition of Personal Genome Diagnostics

LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.

LabCorp (LH) Expands Clinical Laboratory Services With New Pact

San Diego, California--(Newsfile Corp. - February 10, 2022) - Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims Laboratory Corporation of America Holdings ("Labcorp" or the "Company") (NYSE: LH) and its officers and directors for violations of federal securities laws.On January 1, 2022, New York Times released an article regarding the efficacy of Labcorp and other screening labs for certain prenatal tests. The article states that, "A Labcorp MaterniT21 lab report tells patients...

(LH) News: Have You Lost Money on Your Quest Diagnostics Investment? Contact Johnson Fistel Regarding Investigation

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2021 Results - Earnings Call Transcript

LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down

LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q4 Earnings and Revenues Beat Estimates

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2021, full-year 2022 guidance and longer-term outlook. “Labcorp's ability to harness science, innovation and technology helped us advance our strategy, effectively respond to the global pandemic, and drive meaningful financial performance throughout 2021,” said Adam Schechter, chairman and CEO of Labcorp. “We experienced Base Busin

News for Labcorp Holdings Inc Stock (LH)